Amber Salzman
Amministratore Delegato presso Epicrispr Biotechnologies, Inc.
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Clarence Machado | M | 60 | 7 anni | |
Chris E. Shaw | M | - |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | - |
George C. Prendergast | M | - |
Lankenau Institute for Medical Research
Lankenau Institute for Medical Research BiotechnologyHealth Technology Lankenau Institute for Medical Research operates as a non-profit biomedical research centre. It provides human health and well being through technology development and the training to the next generation of scientists and physicians. The company was founded in 1917 and is headquartered Wynnewood, PA. | 20 anni |
Lisa Deschamps | F | 52 |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | - |
John Wellenbach | M | - |
Lankenau Institute for Medical Research
Lankenau Institute for Medical Research BiotechnologyHealth Technology Lankenau Institute for Medical Research operates as a non-profit biomedical research centre. It provides human health and well being through technology development and the training to the next generation of scientists and physicians. The company was founded in 1917 and is headquartered Wynnewood, PA. | - |
Graeme Fielder | M | - |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | 4 anni |
Youn Bok Lee | M | - |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | - |
Laurence Barker | M | - |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | - |
Elizabeth Wilkins | F | - |
Lankenau Institute for Medical Research
Lankenau Institute for Medical Research BiotechnologyHealth Technology Lankenau Institute for Medical Research operates as a non-profit biomedical research centre. It provides human health and well being through technology development and the training to the next generation of scientists and physicians. The company was founded in 1917 and is headquartered Wynnewood, PA. | - |
David Berkowitz | M | - |
Lankenau Institute for Medical Research
Lankenau Institute for Medical Research BiotechnologyHealth Technology Lankenau Institute for Medical Research operates as a non-profit biomedical research centre. It provides human health and well being through technology development and the training to the next generation of scientists and physicians. The company was founded in 1917 and is headquartered Wynnewood, PA. | - |
Leila Gordon | F | - |
Lankenau Institute for Medical Research
Lankenau Institute for Medical Research BiotechnologyHealth Technology Lankenau Institute for Medical Research operates as a non-profit biomedical research centre. It provides human health and well being through technology development and the training to the next generation of scientists and physicians. The company was founded in 1917 and is headquartered Wynnewood, PA. | - |
Lance Colwell | M | - |
Ohana Biosciences, Inc.
Ohana Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Ohana Biosciences, Inc. operates early stage biotechnology firm. The company is headquartered in Cambridge, MA. | - |
Michael Rosenblatt | M | - |
Ohana Biosciences, Inc.
Ohana Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Ohana Biosciences, Inc. operates early stage biotechnology firm. The company is headquartered in Cambridge, MA. | - |
Do Young Lee | M | - |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | - |
Nihal Sinha | M | - |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | - |
Benson Cheng | M | - |
Epicrispr Biotechnologies, Inc.
Epicrispr Biotechnologies, Inc. Miscellaneous Commercial ServicesCommercial Services Epicrispr Biotechnologies, Inc. is a leading epigenetic editing company based in South San Francisco, CA. The company leverages the power of CRISPR without cutting DNA through its proprietary Gene Expression Modulation System (GEMS), which includes the smallest Cas protein known to work in human cells. Epic's lead program is in IND-enabling studies for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and additional programs seek to address alpha-1 antitrypsin deficiency (A1AD), heterozygous familial hypercholesterolemia (HeFH), and other indications. The company is financially backed by Horizons Ventures and other leading investors. The company was founded by Lei Stanley Qi, and the CEO is Amber Salzman. | - |
Karen Gotting Smith | M | - |
Lankenau Institute for Medical Research
Lankenau Institute for Medical Research BiotechnologyHealth Technology Lankenau Institute for Medical Research operates as a non-profit biomedical research centre. It provides human health and well being through technology development and the training to the next generation of scientists and physicians. The company was founded in 1917 and is headquartered Wynnewood, PA. | - |
I. Wistar Morris | M | - |
Lankenau Institute for Medical Research
Lankenau Institute for Medical Research BiotechnologyHealth Technology Lankenau Institute for Medical Research operates as a non-profit biomedical research centre. It provides human health and well being through technology development and the training to the next generation of scientists and physicians. The company was founded in 1917 and is headquartered Wynnewood, PA. | - |
Tim Funnell | M | - |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | 3 anni |
Sara Senior | F | - |
Lankenau Institute for Medical Research
Lankenau Institute for Medical Research BiotechnologyHealth Technology Lankenau Institute for Medical Research operates as a non-profit biomedical research centre. It provides human health and well being through technology development and the training to the next generation of scientists and physicians. The company was founded in 1917 and is headquartered Wynnewood, PA. | - |
Paul B. Gilman | M | 69 |
Lankenau Institute for Medical Research
Lankenau Institute for Medical Research BiotechnologyHealth Technology Lankenau Institute for Medical Research operates as a non-profit biomedical research centre. It provides human health and well being through technology development and the training to the next generation of scientists and physicians. The company was founded in 1917 and is headquartered Wynnewood, PA. | - |
Alice Chase | F | - |
Lankenau Institute for Medical Research
Lankenau Institute for Medical Research BiotechnologyHealth Technology Lankenau Institute for Medical Research operates as a non-profit biomedical research centre. It provides human health and well being through technology development and the training to the next generation of scientists and physicians. The company was founded in 1917 and is headquartered Wynnewood, PA. | - |
Jonathan Fox | M | 66 |
Lankenau Institute for Medical Research
Lankenau Institute for Medical Research BiotechnologyHealth Technology Lankenau Institute for Medical Research operates as a non-profit biomedical research centre. It provides human health and well being through technology development and the training to the next generation of scientists and physicians. The company was founded in 1917 and is headquartered Wynnewood, PA. | - |
Matthew McAviney | M | - |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | - |
Scott K. Dessain | M | - |
Lankenau Institute for Medical Research
Lankenau Institute for Medical Research BiotechnologyHealth Technology Lankenau Institute for Medical Research operates as a non-profit biomedical research centre. It provides human health and well being through technology development and the training to the next generation of scientists and physicians. The company was founded in 1917 and is headquartered Wynnewood, PA. | - |
David Sable | M | 65 |
Ohana Biosciences, Inc.
Ohana Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Ohana Biosciences, Inc. operates early stage biotechnology firm. The company is headquartered in Cambridge, MA. | 4 anni |
David Berry | M | 47 |
Ohana Biosciences, Inc.
Ohana Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Ohana Biosciences, Inc. operates early stage biotechnology firm. The company is headquartered in Cambridge, MA. | - |
J. Goater | M | 48 |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | 1 anni |
Michael Rosenblatt | M | 76 |
Ohana Biosciences, Inc.
Ohana Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Ohana Biosciences, Inc. operates early stage biotechnology firm. The company is headquartered in Cambridge, MA. | 8 anni |
Peter Hessenbruch Havens | M | 70 |
Lankenau Institute for Medical Research
Lankenau Institute for Medical Research BiotechnologyHealth Technology Lankenau Institute for Medical Research operates as a non-profit biomedical research centre. It provides human health and well being through technology development and the training to the next generation of scientists and physicians. The company was founded in 1917 and is headquartered Wynnewood, PA. | - |
John Mendlein | M | 64 |
Ohana Biosciences, Inc.
Ohana Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Ohana Biosciences, Inc. operates early stage biotechnology firm. The company is headquartered in Cambridge, MA. | - |
Gregory Summe | M | 68 |
Ohana Biosciences, Inc.
Ohana Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Ohana Biosciences, Inc. operates early stage biotechnology firm. The company is headquartered in Cambridge, MA. | - |
Peter R. Kowey | M | - |
Lankenau Institute for Medical Research
Lankenau Institute for Medical Research BiotechnologyHealth Technology Lankenau Institute for Medical Research operates as a non-profit biomedical research centre. It provides human health and well being through technology development and the training to the next generation of scientists and physicians. The company was founded in 1917 and is headquartered Wynnewood, PA. | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Leone Patterson | F | 61 | 5 anni | |
Steven Schwartz | M | 62 | 11 anni | |
Robert Dolski | M | 54 | 1 anni | |
Elizabeth Hougen | F | 62 | - | |
John McLaughlin | M | 72 | 2 anni | |
Samuel Barone | M | 51 | 3 anni | |
Edward Fitzgerald | M | 68 | 3 anni | |
Michael MacLean | M | 58 | 3 anni | |
Richard Spivey | M | 74 | - | |
Barbara Yanni | F | 69 | 1 anni | |
Sandy Smith | M | 77 | 3 anni | |
B. Parshall | F | 70 | 5 anni | |
Elaine Hochberg | F | 67 | 3 anni | |
Brett Monia | M | 62 | - | |
Eric Carter | M | 72 | 4 anni | |
Linda Neuman | M | 59 | 1 anni | |
Guriqbal S. Basi | M | 67 | - | |
Michael Yang | M | 62 | 1 anni | |
Melissa M. Yoon | F | - | - | |
William T. Andrews | M | 60 | - | |
Lisa Johnson-Pratt | M | 60 | - | |
Tracy Palmer Berns | F | - | - | |
Matthieu Coutet | M | - |
Annapurna Therapeutics SAS
Annapurna Therapeutics SAS BiotechnologyHealth Technology Annapurna Therapeutics SAS operates as a gene therapy company. Its therapy restored cardiac function and reversed pathological heart enlargement in mice that had already progressed to heart failure. The company was founded by Pierre Bougneres, Hélène Puccio, Amber Salzman, Patrick Aubourg and Ronald G. Crystal and is headquartered in Paris, France. | - |
Athena Countouriotis | M | 52 | 1 anni | |
Shirley Braun | M | - | 1 anni | |
Kianoush Motesharei | M | 54 | - | |
Chahra Khaoua Epouse Louafi | F | 53 |
Annapurna Therapeutics SAS
Annapurna Therapeutics SAS BiotechnologyHealth Technology Annapurna Therapeutics SAS operates as a gene therapy company. Its therapy restored cardiac function and reversed pathological heart enlargement in mice that had already progressed to heart failure. The company was founded by Pierre Bougneres, Hélène Puccio, Amber Salzman, Patrick Aubourg and Ronald G. Crystal and is headquartered in Paris, France. | - |
Mark Guerin | M | 55 |
CardioKine, Inc.
CardioKine, Inc. Pharmaceuticals: MajorHealth Technology CardioKine, Inc. develops drugs and pharmaceuticals for the treatment and prevention of heart failure. The company was founded by Arthur Michael Feldman, James Mervis, Paul-Andre de Lame and Michael Juliano in 2004 and is headquartered in Pittsburgh, PA. | 2 anni |
Cesare Orlandi | M | 73 |
CardioKine, Inc.
CardioKine, Inc. Pharmaceuticals: MajorHealth Technology CardioKine, Inc. develops drugs and pharmaceuticals for the treatment and prevention of heart failure. The company was founded by Arthur Michael Feldman, James Mervis, Paul-Andre de Lame and Michael Juliano in 2004 and is headquartered in Pittsburgh, PA. | 4 anni |
Louis St. Laurence O'Dea | M | 73 | 4 anni | |
Federica O’Brien | F | 66 |
CardioKine, Inc.
CardioKine, Inc. Pharmaceuticals: MajorHealth Technology CardioKine, Inc. develops drugs and pharmaceuticals for the treatment and prevention of heart failure. The company was founded by Arthur Michael Feldman, James Mervis, Paul-Andre de Lame and Michael Juliano in 2004 and is headquartered in Pittsburgh, PA. | 4 anni |
Lauren Glaser | F | - | - | |
Carlo Russo | M | 71 | - | |
Michael Dennis Price | M | 66 | - | |
Joseph Klein | M | 62 | 1 anni | |
Carla Poulson | F | - | - |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 57 | 82.61% |
Regno Unito | 10 | 14.49% |
Francia | 2 | 2.90% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Amber Salzman
- Contatti personali